Respiratory Syncytial Virus Diseases
📧 Sign up to get email alerts when something new happens for Respiratory Syncytial Virus Diseases.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-21EMA Authorised: Abrysvo (respiratory syncytial virus vaccine (bivalent, recombinant)) — Pfizer Europe MA EEIG
EMA has authorised Abrysvo, a bivalent recombinant RSV vaccine, for the prevention of respiratory syncytial virus infections.